AI assistant
Lonza Group AG — Capital/Financing Update 2024
Aug 28, 2024
923_iss_2024-08-28_b9f05a41-f108-47ce-ac10-32927d8a06e1.html
Capital/Financing Update
Open in viewerOpens in your device viewer
Lonza Group AG / Key word(s): Bond
Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds
28.08.2024 / 18:31 CET/CEST
Basel, Switzerland, 28 August 2024 – Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of its dual tranche EUR 1.2 billion straight bonds. The bonds have a maturity of six and ten years with coupons of 3.25% and 3.50% respectively.
The issuer is Lonza Finance International NV and the bonds will be guaranteed by Lonza. Lonza will apply for the listing of the bonds on the Luxembourg Stock Exchange (Regulated Market). The proceeds of the bonds will be used for general corporate purposes, including the financing of acquisitions and refinancing of existing debt.
Lonza’s issuer rating is currently BBB+ (S&P Global Ratings) with a stable outlook.
A consortium comprising of BofA, Citibank, HSBC, JP Morgan and UBS were mandated to place the bond as Joint Active Bookrunners.
Key Data
| Six Year Tranche | Ten Year Tranche | |
| Issue Size | EUR 600 million | EUR 600 million |
| Expected Payment Date | 04 September 2024 | 04 September 2024 |
| Maturity | 04 September 2030 | 04 September 2034 |
| Issue Price | 99.448 percent | 98.361 percent |
| Redemption Price | 100 percent | 100 percent |
| Coupon | 3.25 percent p.a. | 3.50 percent p.a. |
About Lonza
Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments.
Our business is structured to meet our customers' complex needs across four divisions: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Our company generated sales of CHF 3.1 billion with a CORE EBITDA of CHF 893 million in Half-Year 2024. Find out more at www.lonza.com
Follow @Lonza on LinkedIn
Follow @LonzaGroup on X
Lonza Contact Details
Victoria Morgan
Head of External Communications
Lonza Group Ltd
Tel +41 61 316 2283
Daniel Buchta
Head of Investor Relations
Lonza Group Ltd
Tel +41 61 316 2985
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.
All trademarks belong to Lonza and are registered in CH, US and/or EU, or belong to their respective third-party owners and are used only for informational purposes.
Privacy Policy link
To immediately delete all the data
End of Media Release
| Language: | English |
| Company: | Lonza Group AG |
| Münchensteinerstrasse 38 | |
| 4052 Basel | |
| Switzerland | |
| Phone: | +4161 316 81 11 |
| Internet: | www.lonza.com |
| ISIN: | CH0013841017 |
| Valor: | 1384101 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1977139 |
| End of News | EQS News Service |
1977139 28.08.2024 CET/CEST